{"id":"W2790816436","doi":"10.1016/s0140-6736(18)30475-6","title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":925,"is_retracted":false,"has_abstract":false,"ca_institutions":"NeuroRx Research (Canada); McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Placebo; Expanded Disability Status Scale; Clinical endpoint; Multiple sclerosis; Internal medicine; Clinical trial; Randomized controlled trial; Physical therapy; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2042846764689597,"score_gpt":0.4062930836065874,"score_spread":0.2020084071376277,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}